Hims cancels plans to sell compounded GLP-1 pill after FDA backlash
biopharmadive.com
biopharmadive.com
FDA backlash + Novo Nordisk filed their lawsuit about 30 minutes after HIMS announced the plan. Not exaggerating: NVO evidently had it in the barrel, ready to fire the moment the first press release dropped.